Serum uric acid trajectories and risk of metabolic dysfunction-associated steatotic liver disease in China: a 2019-2021 cohort health survey

被引:0
作者
Shi, Dan [1 ]
Tan, Qilong [2 ,3 ]
Zhang, Yong [1 ,4 ]
Qi, Xiaoya [4 ]
Xu, Xiaoyang [4 ]
Xu, Guoqiong [4 ]
Bai, Ruixue [4 ]
Deng, Jing [4 ]
Chen, Mengxue [4 ]
Jiang, Tao [4 ]
Mei, Ying [4 ]
机构
[1] Chongqing Med Univ, Sch Publ Hlth, Chongqing 400016, Peoples R China
[2] Zhejiang Univ, Sch Publ Hlth, Sch Med, Hangzhou 310058, Zhejiang, Peoples R China
[3] Harbin Med Univ, Sch Publ Hlth, Harbin 150081, Heilongjiang, Peoples R China
[4] Chongqing Med Univ, Hosp 2, Dept Hlth Management, Chongqing 400011, Peoples R China
关键词
MASLD; Uric acid; Trajectory; China; FATTY LIVER; HEPATIC STEATOSIS; HYPERURICEMIA; HYPERTENSION; GENERATION; STRESS;
D O I
10.1186/s12889-024-21214-0
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
ObjectiveTo investigate the associations between serum uric acid (UA) trajectories and the risk of metabolic dysfunction-associated steatotic liver disease (MASLD) in large cohort survey 2019-2021.MethodsThis cohort health survey included 11,644 participants without MASLD before January 1, 2021. Among them, 5578 (47.90%) were men and 6066 (52.10%) were women. The group-based trajectory model method was applied to identify serum UA trajectories from January 1, 2019, to December 30, 2021. New-onset MASLD events in 2021 were treated as outcomes. A logistic regression model was used to assess associations between UA trajectories and incidence of MASLD.ResultsFour distinct serum UA trajectories among both sexes were identified: "low-stable" trajectory 1 (n = 783 men; n = 1143 women), "moderate-moderate increasing" trajectory 2 (n = 2794 men; n = 3266 women), "moderate high-moderate increasing" trajectory 3 (n = 1660 men; n = 1464 women), and "high-increasing" trajectory 4 (n = 341 men; n = 193 women). During the 3-year follow-up period, 840 (15.06%) men and 408 (6.72%) women developed MASLD, respectively. Compared with the trajectory 1 group, the trajectory 4 group had the highest risk (odds ration [OR] 2.99 [95% confidence interval {CI} 1.70, 5.24] for men; OR 2.37 [95% CI 1.04, 5.33] for women), followed by the trajectory 3 (OR 2.23 [95% CI 1.52, 3.30] for men; OR 2.37 [95% CI 1.45, 3.92] for women) and trajectory 2 (OR 1.43 [95% CI 1.07, 1.94] for men; OR 1.37 [95% CI 0.93, 2.03] for women) groups.ConclusionsHigh serum UA trajectories were independent risk factors for MASLD in both sexes, which is critical for informing prevention and treatment strategies in public health initiatives and clinical practice.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study
    Moon, Joon Ho
    Jeong, Seogsong
    Jang, Heejoon
    Koo, Bo Kyung
    Kim, Won
    ECLINICALMEDICINE, 2023, 65
  • [22] Metabolic dysfunction-associated steatotic liver disease: Evolution of the final terminology
    Portincasa, Piero
    Baffy, Gyorgy
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2024, 124 : 35 - 39
  • [23] Association between serum uric acid levels and long-term mortality of metabolic dysfunction-associated fatty liver disease: a nationwide cohort study
    Liu, Zhening
    Wang, Qinqiu
    Huang, Hangkai
    Wang, Xinyu
    Xu, Chengfu
    DIABETOLOGY & METABOLIC SYNDROME, 2023, 15 (01)
  • [24] Establishing of a risk prediction model for metabolic dysfunction-associated steatotic liver disease: a retrospective cohort study
    Li, Nan
    Liu, Chenbing
    Lu, Zhangfan
    Wu, Wenjian
    Zhang, Feng
    Qiu, Lihong
    Shen, Chao
    Sheng, Di
    Liu, Zhong
    BMC GASTROENTEROLOGY, 2025, 25 (01)
  • [25] Association of uric acid levels with the development of metabolic dysfunction-associated and metabolic and alcohol-related/associated steatotic liver disease: a study on Japanese participants undergoing health checkups
    Fukuda, Tatsuya
    Akihisa, Taro
    Okamoto, Takahiro
    Fukaishi, Takahiro
    Kawakami, Akio
    Tanaka, Makoto
    Yamada, Tetsuya
    Monzen, Koshiro
    ENDOCRINE JOURNAL, 2025,
  • [26] Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective
    Eskridge, Wayne
    Cryer, Donna R.
    Schattenberg, Joern M.
    Gastaldelli, Amalia
    Malhi, Harmeet
    Allen, Alina M.
    Noureddin, Mazen
    Sanyal, Arun J.
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (19)
  • [27] Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated with Increased Risk of Kidney Cancer: A Nationwide Study
    Oh, Juyeon
    Kim, Beom Kyung
    Yoon, Jin-Ha
    Lee, Hyung Ho
    Park, Heejoo
    Lee, Jian
    Park, Youngsun
    Yun, Byungyoon
    Chung, Jinsoo
    CANCERS, 2024, 16 (18)
  • [28] Role of Glucocorticoids in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Polyzos, Stergios A.
    Targher, Giovanni
    CURRENT OBESITY REPORTS, 2024, 13 (02) : 242 - 255
  • [29] A European Survey to Identify Challenges in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease
    Castera, Laurent
    Alazawi, William
    Bugianesi, Elisabetta
    Caussy, Cyrielle
    Federici, Massimo
    Romero-Gomez, Manuel
    Schattenberg, Joern M.
    Basuroy, Ron
    Prasad, Preethy
    Estulin, Dmitry
    Lazarus, Jeffrey V.
    LIVER INTERNATIONAL, 2025, 45 (02)
  • [30] Update in lean metabolic dysfunction-associated steatotic liver disease
    Sato-Espinoza, Karina
    Chotiprasidhi, Perapa
    Huaman, Mariella R.
    Diaz-Ferrer, Javier
    WORLD JOURNAL OF HEPATOLOGY, 2024, 16 (03) : 452 - 464